|
|
Article: Aerovance Announces Data Presentations on AER-002 at 18th Annual North American Cystic Fibrosis Conference; Data Provide Strong Rationale for Entry of AER-002 Into Clinic in First Half of 2005.
- Article from:
- PR Newswire
- Article date:
- October 15, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
ST. LOUIS, Mo., Oct. 15 /PRNewswire/ -- Aerovance, Inc. announced today that researchers presented preclinical data today at the 18th Annual North American Cystic Fibrosis (CF) Conference that provide strong support for moving the Company's second lead product, AER-002 (also known as SPINT2 and Bikunin), into the clinic.
"These studies demonstrate AER-002 could prove to be a potent new therapy for CF patients," said Rick Fuller, M.D., Chief Medical Officer of Aerovance. "AER-002 could address significant medical issues for CF patients and we are excited to continue our preclinical development work with this product candidate with the goal of entering the clinic ...